Which drug protects the heart better in giant cell arteritis?

NCT ID NCT07459335

Completed Knowledge-focused Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 1,600 people with giant cell arteritis, a condition that inflames blood vessels and raises heart risks. Researchers compared tocilizumab and methotrexate to see which better prevents heart attacks, strokes, or death. Using French health data, they analyzed real-world outcomes to guide treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab and methotrexate
What this could lead to: If this study shows one drug is better, it could guide doctors to choose the safer option for heart health in giant cell arteritis patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES GIANT CELL ARTERITIS (GCA)

Contacts and locations

Locations

APHP_ Hôpital Pitié-Salpêtrière

Paris, 75013, France
APHP_ Hôpital Saint-Antoine

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.